FY2025 EPS Estimates for Nkarta Increased by Leerink Partnrs

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of Nkarta in a research note issued on Tuesday, November 11th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($1.41) per share for the year, up from their prior estimate of ($1.48). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.55) EPS and FY2029 earnings at ($1.15) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.03.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nkarta in a report on Friday, October 31st. Wall Street Zen upgraded Nkarta from a "sell" rating to a "hold" rating in a research report on Saturday, October 25th. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th. Finally, Stifel Nicolaus reduced their target price on shares of Nkarta from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nkarta has a consensus rating of "Moderate Buy" and an average price target of $13.25.

View Our Latest Stock Report on Nkarta

Nkarta Price Performance

Shares of NKTX opened at $1.96 on Thursday. Nkarta has a 1-year low of $1.31 and a 1-year high of $3.18. The stock has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.86. The firm has a 50 day simple moving average of $2.13 and a 200-day simple moving average of $2.01.

Hedge Funds Weigh In On Nkarta

A number of hedge funds have recently made changes to their positions in NKTX. Nuveen LLC purchased a new position in shares of Nkarta in the 1st quarter worth $258,000. Charles Schwab Investment Management Inc. increased its stake in Nkarta by 18.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 147,551 shares of the company's stock worth $271,000 after acquiring an additional 22,538 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Nkarta by 54.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company's stock worth $3,800,000 after purchasing an additional 730,260 shares during the period. Samalin Investment Counsel LLC raised its holdings in shares of Nkarta by 81.4% in the 1st quarter. Samalin Investment Counsel LLC now owns 153,425 shares of the company's stock worth $282,000 after purchasing an additional 68,850 shares during the period. Finally, Monaco Asset Management SAM acquired a new position in shares of Nkarta in the 1st quarter valued at about $1,496,000. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

Featured Articles

• Five stocks we like better than Nkarta
• 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
• 3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming
• With Risk Tolerance, One Size Does Not Fit All
• As Warren Buffett Nears His Exit, Berkshire's Amassed Record Cash
• Buy P&G Now, Before It Sets A New All-Time High
• Rare Earth Stocks: The Truce That Isn't a Truce

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nkarta Right Now?

Before you consider Nkarta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.

While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here